UOL Group stock ends near S$9.39 high as new community push lands — what to watch next
10 January 2026
1 min read

UOL Group stock ends near S$9.39 high as new community push lands — what to watch next

Singapore, Jan 10, 2026, 15:33 SGT — Market closed

  • UOL shares ended Friday at S$9.35, up 0.5%, after rising 1.6% a day earlier
  • UOL said it will expand its Community Uplift Programme to Bukit Merah and donate S$150,000 to ComLink+ efforts
  • Focus shifts to Monday’s reopen and the next results timetable

UOL Group Limited shares closed at S$9.35 on Friday, up 0.5% from the previous session, after gaining 1.6% on Thursday and pushing back toward recent highs. The stock traded between S$9.28 and S$9.39 and saw 1.43 million shares change hands, the company’s stock page showed. 1

Why it matters now: the move comes as Singapore equities ended the week slightly higher, keeping a bid under rate-sensitive names such as developers. The Straits Times Index rose 0.1% on Friday, with regional markets firmer, The Business Times reported. 2

Investors are also weighing policy signals around the local market’s plumbing. Singapore’s central bank said on Friday it is seeking feedback on legal changes aimed at facilitating dual listings on SGX and Nasdaq, including provisions that would allow practices common in the U.S. such as share buybacks under safe-harbour rules. 3

Separately, UOL said on Saturday it will expand the UOL-PPHG Community Uplift Programme to support ComLink+ families in Bukit Merah, adding to its earlier work in Jurong West. The group said it will contribute S$150,000 in cash donations — S$100,000 to ComLink+ @ Jurong West and S$50,000 to ComLink+ @ Bukit Merah — and said participation among children and youths in Jurong West rose to 120 in 2025 from 57 at launch. “At UOL, we are committed to helping children and their families achieve their full potential,” Chief Executive Liam Wee Sin said.

For traders, the levels are plain. A break above Friday’s S$9.39 high would mark fresh territory for the month; a slip back below S$9.28 would unwind a chunk of the past two sessions’ gains.

The next catalyst is likely to be earnings-related. MarketScreener’s calendar lists UOL’s next earnings release for the fourth quarter of 2025 as projected for March 2, though companies can shift dates. 4

But the upside case can wobble fast. UOL is exposed to swings in Singapore’s housing cycle and borrowing costs, and its hotel arm adds sensitivity to travel demand; a cautious tone on launches or margins could test a stock that has moved up quickly in early January.

With the market shut on Saturday, the first test is the next SGX session on Monday (Jan 12). After that, attention turns to the next results update and any read-through on project launches and hotel bookings.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Genting Singapore stock edges up as Resorts World Sentosa readies POP MART Lunar New Year draw
Previous Story

Genting Singapore stock edges up as Resorts World Sentosa readies POP MART Lunar New Year draw

Sembcorp Industries stock dips as Sprng Energy bid talk resurfaces; Alinta vote nears
Next Story

Sembcorp Industries stock dips as Sprng Energy bid talk resurfaces; Alinta vote nears

Go toTop